The DOI matches its Crossref record; 475 of the 475 references it cites were found in a registry or an index.
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Open accessAbstract
Monoclonal antibodies (mAbs) have become one of the most important classes of biopharmaceutical products, and they continue to dominate the universe of biopharmaceutical markets in terms of approval and sales. They are the most profitable single product class, where they represent six of the top ten selling drugs. At the beginning of the 1990s, an in vitro antibody selection technology known as antibody phage display was developed by John McCafferty and Sir. Gregory Winter that enabled the discovery of human antibodies for diverse applications, particularly antibody-based drugs. They created combinatorial antibody libraries on filamentous phage to be utilized for generating antigen specific antibodies in a matter of weeks. Since then, more than 70 phage–derived antibodies entered clinical studies and 14 of them have been approved. These antibodies are indicated for cancer, and non-cancer medical conditions, such as inflammatory, optical, infectious, or immunological diseases. Antibody phage display has proven to be a powerful, versatile platform for antibodies discovery and development. This review will illustrate the utility of phage display as a powerful platform for therapeutic antibodies discovery and describe in detail all the approved mAbs derived from phage display.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 475
Camidge, D. R., Herbst, R. S., Gordon, M. S., Eckhardt, S. G., Kurzrock, R., Durbin, B., Ing, J., Tohnya, T. M., Sager, J., Ashkenazi, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1267 · Cited by 169
Therapeutic Applications of Monoclonal Antibodies
Berger, M., Shankar, V., & Vafai, A. (2002) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200207000-00004 · Cited by 168
Fuchs, C. S., Azevedo, S., Okusaka, T., Van Laethem, J.-L., Lipton, L. R., Riess, H., Szczylik, C., Moore, M. J., Peeters, M., Bodoky, G., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv027 · Cited by 168
Miller, K., Cortes, J., Hurvitz, S. A., Krop, I. E., Tripathy, D., Verma, S., Riahi, K., Reynolds, J. G., Wickham, T. J., Molnar, I., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2385-z · Cited by 168
Drugs derived from phage display: From candidate identification to clinical practice
Nixon, A. E., Sexton, D. J., & Ladner, R. C. (2014) · mAbs · doi:10.4161/mabs.27240 · Cited by 167
IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor
Rowinsky, E. K., Youssoufian, H., Tonra, J. R., Solomon, P., Burtrum, D., & Ludwig, D. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1109 · Cited by 167
Potent Neutralization of Hendra and Nipah Viruses by Human Monoclonal Antibodies
Zhu, Z., Dimitrov, A. S., Bossart, K. N., Crameri, G., Bishop, K. A., Choudhry, V., Mungall, B. A., Feng, Y.-R., Choudhary, A., Zhang, M.-Y., et al. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.891-899.2006 · Cited by 167
The discovery and development of belimumab: the anti-BLyS–lupus connection
Stohl, W., & Hilbert, D. M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2076 · Cited by 166
H3‐rules: identification of CDR‐H3 structures in antibodies
Shirai, H., Kidera, A., & Nakamura, H. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00821-2 · Cited by 166
Fisher, T. S., Kamperschroer, C., Oliphant, T., Love, V. A., Lira, P. D., Doyonnas, R., Bergqvist, S., Baxi, S. M., Rohner, A., Shen, A. C., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1237-1 · Cited by 166
Bakker, A. B. H., Marissen, W. E., Kramer, R. A., Papaneri, A. B., Weldon, W. C., Niezgoda, M., Hanlon, C. A., Thijsse, S., Backus, H. H. J., de Kruif, J., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.14.9062-9068.2005 · Cited by 166
Prassler, J., Thiel, S., Pracht, C., Polzer, A., Peters, S., Bauer, M., Nörenberg, S., Stark, Y., Kölln, J., Popp, A., et al. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.08.012 · Cited by 165
Measuring and Increasing Protein Solubility
Trevino, S. R., Scholtz, J. M., & Pace, C. N. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21327 · Cited by 163
Developing therapeutic monoclonal antibodies at pandemic pace
Kelley, B. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0512-5 · Cited by 163
Weigel, B., Malempati, S., Reid, J. M., Voss, S. D., Cho, S. Y., Chen, H. X., Krailo, M., Villaluna, D., Adamson, P. C., & Blaney, S. M. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.24605 · Cited by 161
Concepts in antibody phage display
Carmen, S., & Jermutus, L. (2002) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/1.2.189 · Cited by 161
Belimumab: A Review in Systemic Lupus Erythematosus
Blair, H. A., & Duggan, S. T. (2018) · Drugs · doi:10.1007/s40265-018-0872-z · Cited by 161
Phage Display Libraries for Antibody Therapeutic Discovery and Development
Almagro, J. C., Pedraza-Escalona, M., Arrieta, H. I., & Pérez-Tapia, S. M. (2019) · Antibodies · doi:10.3390/antib8030044 · Cited by 161
Schier, R., Marks, J. D., Wolf, E. J., Apelld, G., Won, C., McCartney, J. E., Bookman, M. A., Huston, J. S., Houston, L. L., Weiner, L. M., et al. (1995) · Immunotechnology · doi:10.1016/1380-2933(95)00007-0 · Cited by 159
Engineering antibodies by yeast display
Boder, E. T., Raeeszadeh‐Sarmazdeh, M., & Price, J. V. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.009 · Cited by 158
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab
Raghu, G., Martínez, F. J., Brown, K. K., Costabel, U., Cottin, V., Wells, A. U., LANCASTER, L. H., Gibson, K. F., Haddad, T., Agarwal, P., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01558-2014 · Cited by 158
Cancer immunologists scoop medicine Nobel prize
Ledford, H. K., Else, H., & Warren, M. (2018) · Nature · doi:10.1038/d41586-018-06751-0 · Cited by 158
Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., Cain, J., Tam, R., Cheng, C.-Y., Evans, J., et al. (2017) · Science Advances · doi:10.1126/sciadv.1700090 · Cited by 157
The role of IL 23 in the treatment of psoriasis
Puig, L. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1292137 · Cited by 156
Hanna, M. G., Badrising, U. A., Benvéniste, O., Lloyd, T. E., Needham, M., Chinoy, H., Aoki, M., Machado, P., Liang, C., Reardon, K. A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30200-5 · Cited by 156
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
Lukas, R. V., Rodon, J. A., Becker, K. P., Wong, E. T., Shih, K. C., Touat, M., Fassò, M., Osborne, S., Molinero, L. L., O'Hear, C. E., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2955-9 · Cited by 154
Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J., & Pastan, I. H. (2002) · PubMed · Cited by 153
Assessing the Immunogenicity of Biopharmaceuticals
Pineda, C., Hernández, G. C., Jacobs, I. A., Alvarez, D. F., & Carini, C. (2016) · BioDrugs · doi:10.1007/s40259-016-0174-5 · Cited by 153
Glorieux, F. H., Devogelaer, J., Durigova, M., Goemaere, S., Hemsley, S., Jakob, F. J., JUNKER, U., Ruckle, J., Seefried, L., & Winkle, P. J. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3143 · Cited by 153
Vincenti, F. G., Fervenza, F. C., Campbell, K. N., Encarnación, M. M. D., Gesualdo, L., Nelson, P., Praga, M., Radhakrishnan, J., Sellin, L. K., Singh, A. K., et al. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.03.011 · Cited by 153
Playford, E. G., Munro, T. P., Mahler, S. M., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30634-6 · Cited by 152
Self-citationNagy, Z. A., Hubner, B., Löhning, C., Rauchenberger, R., Reiffert, S. U., Thomassen-Wolf, E., Zahn, S., Leyer, S., Schier, E. M., Zahradnik, A., et al. (2002) · Nature Medicine · doi:10.1038/nm736 · Cited by 149
Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., et al. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402306 · Cited by 148
Phage Display for the Generation of Antibodies for Proteome Research, Diagnostics and Therapy
Schirrmann, T., Meyer, T., Schütte, M., Frenzel, A., & Hust, M. (2011) · Molecules · doi:10.3390/molecules16010412 · Cited by 148
Rapid and accurate in silico solubility screening of a monoclonal antibody library
Sormanni, P., Amery, L., Ekizoglou, S., Vendruscolo, M., & Popovic, B. (2017) · Scientific Reports · doi:10.1038/s41598-017-07800-w · Cited by 148
Strober, B. E., Crowley, J., Yamauchi, P. S., et al. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10419.x · Cited by 146
Third generation antibody discovery methods: in silico rational design
Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00523k · Cited by 146
Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization
Huang, L., Biolsi, S., Bales, K. R., & Kuchibhotla, U. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.11.012 · Cited by 144
Smolen, J. S., Agarwal, S. K., Ilivanova, E. P., Xu, X. L., Ye, M., Zhuang, Y., Nnane, I. P., Radziszewski, W., Greenspan, A. J., Beutler, A. M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209831 · Cited by 144
Protein selection using yeast surface display
Gera, N., Hussain, M., & Rao, B. M. (2012) · Methods · doi:10.1016/j.ymeth.2012.03.014 · Cited by 143
Prang, N. S., Preithner, S., Brischwein, K., Göster, P., Wöppel, A., Müller, J., Steiger, C., Peters, M. J., Baeuerle, P. A., & da Silva, A. J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602310 · Cited by 143
Lloyd, C., Lowe, D., Edwards, B. M., Welsh, F., Dilks, T., Hardman, C. H., & Vaughan, T. J. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn058 · Cited by 142
Identification of specificity‐determining residues in antibodies
PADLAN, E. A., Abergel, C., & Tipper, J. P. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.1.7821752 · Cited by 140
Rauchenberger, R., Borges, E., Thomassen-Wolf, E., Rom, E., Adar, R., Yaniv, Y., Malka, M., Chumakov, I., Kotzer, S., Resnitzky, D., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303164200 · Cited by 139
Münster, P. N., Krop, I. E., LoRusso, P. M., Ma, C. X., Siegel, B. A., Shields, A. F., Molnár, I., Wickham, T. J., Reynolds, J. G., Campbell, K., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0235-2 · Cited by 139
Menéndez, A., & Scott, J. K. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.09.048 · Cited by 138
Anthrax toxin: a tripartite lethal combination1
Ascenzi, P., Visca, P., Ippolito, G., Spallarossa, A., Bolognesi, M., & Montecucco, C. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03609-8 · Cited by 137
Generation and analysis of the improved human HAL9/10 antibody phage display libraries
Kügler, J., Wilke, S., Meier, D., Tomszak, F., Frenzel, A., Schirrmann, T., Dübel, S., Garritsen, H., Hock, B. M., Toleikis, L., et al. (2015) · BMC Biotechnology · doi:10.1186/s12896-015-0125-0 · Cited by 137
Lü, D., Jimenez, X., Zhang, H., Böhlen, P., Witte, L., & Zhu, Z. (2001) · International Journal of Cancer · doi:10.1002/ijc.1634 · Cited by 136
Mackey, J. R., Ramos-Vázquez, M., Lipatov, O. N., McCarthy, N. J., Krasnozhon, D., Семиглазов, В. Ф., Manikhas, A., Gelmon, K. A., Konecny, G. E., Webster, M. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1513 · Cited by 136
Jayne, D. R. W., Blockmans, D., Luqmani, R. A., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40802 · Cited by 136
Huang, J. X., Bishop‐Hurley, S. L., & Cooper, M. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00567-12 · Cited by 134
Dobson, C., Devine, P. W. A., Phillips, J. J., Higazi, D. R., Lloyd, C., Popovic, B., Arnold, J., Buchanan, A. G., Lewis, A. R., Goodman, J., et al. (2016) · Scientific Reports · doi:10.1038/srep38644 · Cited by 134
Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., Mattsson, J., Sundberg, A., Vaughan, A. T., Shah, V., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.005 · Cited by 133
Beltran, P. J., Mitchell, P., Chung, Y.-A., Cajulis, E. E., Lu, J., Belmontes, B., Ho, J., Tsai, M. M., Zhu, M., Vonderfecht, S. L., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1171 · Cited by 133
Amiot, A., & Peyrin‐Biroulet, L. (2014) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x14558193 · Cited by 133
Schmidt, M., Scheulen, M. E., Dittrich, C., Obrist, P., Marschner, N. W., Dirix, L. Y., Schmidt, M., Rüttinger, D., Schüler, M., Reinhardt, C., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp314 · Cited by 133
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
Younes, A., Vose, J. M., Zelenetz, A. D., Smith, M. R., Burris, H. A., Ansell, S. M., Klein, J., Halpern, W., Miceli, R. C., Kumm, E., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605987 · Cited by 132
Pappalardo, E. M., Caccia, S., Suffritti, C., Tordai, A., Zingale, L. C., & Cicardi, M. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.05.007 · Cited by 130
High copy display of large proteins on phage for functional selections 1 1Edited by P. E. Wright
Sidhu, S. S., Weiss, G. A., & Wells, J. A. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3465 · Cited by 129
Structural Basis for EGF Receptor Inhibition by the Therapeutic Antibody IMC-11F8
Li, S., Kussie, P. H., & Ferguson, K. M. (2008) · Structure · doi:10.1016/j.str.2007.11.009 · Cited by 129
Garner, A. P., Bialucha, C. U., Sprague, E. R., Garrett, J. T., Sheng, Q., Li, S., Sineshchekova, O., Saxena, P., Sutton, C. R., Chen, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1198 · Cited by 129
Engineering Aggregation-Resistant Antibodies
Perchiacca, J. M., & Tessier, P. M. (2012) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-062011-081052 · Cited by 128
Mårlind, J., Kaspar, M., Trachsel, E., Sommavilla, R., Hindle, S., Bacci, C., Giovannoni, L., & Neri, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5041 · Cited by 127
Burmester, G. R., Feist, E., Sleeman, M., Wang, B., White, B., & Magrini, F. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146225 · Cited by 127
Merkel Cell Carcinoma Therapeutic Update
Cassler, N. M., Merrill, E. D., Bichakjian, C. K., & Brownell, I. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0409-1 · Cited by 127
A Systematic Comparison of Free and Bound Antibodies Reveals Binding-Related Conformational Changes
Sela‐Culang, I., Alon, S., & Ofran, Y. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201493 · Cited by 125
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Wolska, A., & Robak, T. (2019) · Drug Safety · doi:10.1007/s40264-018-0775-7 · Cited by 124
Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors
Merchant, M. S., Geller, J. I., Baird, K., Chou, A. J., Galli, S., Charles, A., Amaoko, M., Rhee, E. H., Price, A. P., Wexler, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1055 · Cited by 123
Vaccaro, C., Bawdon, R. E., Wanjie, S., Ober, R. J., & Ward, E. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606304103 · Cited by 119
Kumar, R., Parray, H. A., Shrivastava, T., Sinha, S., & Luthra, K. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.06.006 · Cited by 119
Introduction to Heavy Chain Antibodies and Derived Nanobodies
Vincke, C., & Muyldermans, S. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-968-6_2 · Cited by 115
Tailored Immune Responses: Novel Effector Helper T Cell Subsets in Protective Immunity
Kara, E. E., Comerford, I., Fenix, K. A., Bastow, C. R., Whyte, C. E., McKenzie, D. R., & McColl, S. R. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003905 · Cited by 114
von Pawel, J., Harvey, J. H., Spigel, D. R., Dediu, M., Reck, M., Cebotaru, C. L., Humphreys, R. C., Gribbin, M., Fox, N. L., & Camidge, D. R. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.12.005 · Cited by 113
Pathogenesis of Hereditary Angioedema
Kaplan, A. P., & Joseph, K. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.04.001 · Cited by 113
Lounder, D. T., Bin, Q., de Min, C., & Jordan, M. B. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018025858 · Cited by 113
Emapalumab: First Global Approval
Al-Salama, Z. T. (2019) · Drugs · doi:10.1007/s40265-018-1046-8 · Cited by 113
[29] Design and use of phage display libraries for the selection of antibodies and enzymes
Viti, F., Nilsson, F. Y., Demartis, S., et al. (2000) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(00)26071-0 · Cited by 108
May, R. D., Monk, P., Cohen, E. S., Manuel, D. V. F. P., Dempsey, F. C., Davis, N. H. E., Dodd, A., Corkill, D. J., Woods, J. M., Joberty-Candotti, C., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01659.x · Cited by 107
Sagoo, G. S., Ahnini, R. T., Barker, J. W. N., Elder, J. T., Nair, R. P., Samuelsson, L., Traupe, H., Trembath, R. C., Robinson, D. A., & Iles, M. M. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22607.x · Cited by 106
Immunocytokines: a review of molecules in clinical development for cancer therapy
List, T., & Neri, D. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s49231 · Cited by 104
Klarenbeek, A., Mazouari, K. E., Desmyter, A., Blanchetot, C., Hultberg, A., Jonge, N. D., Roovers, R. C., Cambillau, C., Spinelli, S., Del‐Favero, J., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1046648 · Cited by 104
Alderson, R. F., Kreitman, R. J., Chen, T., Yeung, P., Herbst, R., Fox, J. A., & Pastan, I. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1456 · Cited by 104
Biologics for the primary care physician: Review and treatment of psoriasis
Schadler, E. D., Ortel, B. J., & Mehlis, S. L. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2018.06.001 · Cited by 104
Murer, P., & Neri, D. (2019) · New Biotechnology · doi:10.1016/j.nbt.2019.04.002 · Cited by 104
Silence, K., Dreier, T., Moshir, M., Ulrichts, P., Gabriëls, S., Saunders, M. J., Wajant, H., Brouckaert, P., Huyghe, L., Hauwermeiren, T. V., et al. (2013) · mAbs · doi:10.4161/mabs.27398 · Cited by 103
Friedbichler, K., Hofmann, M. H., Kroez, M., Ostermann, E., Lamche, H. R., Koessl, C., Borges, E., Pollak, M., Adolf, G. R., & Adam, P. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0598 · Cited by 103
Coloma, M. J., Trinh, R. K., Martinez, A. R., & Morrison, S. L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2162 · Cited by 103
Generating conformation-specific synthetic antibodies to trap proteins in selected functional states
Paduch, M., Koide, A., Uysal, S., Rizk, S. S., Koide, S., & Kossiakoff, A. A. (2012) · Methods · doi:10.1016/j.ymeth.2012.12.010 · Cited by 102
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification
Steidl, S., Ratsch, O., Brocks, B., Dürr, M. C., & Thomassen-Wolf, E. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.07.013 · Cited by 102
A Randomized Phase II b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
Weinblatt, M. E., McInnes, I. B., Kremer, J. M., Miranda, P., Vencovský, J., Guo, X., White, W. I., Ryan, P. C., Godwood, A., Albulescu, M., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40323 · Cited by 101
* (2003) · The American Journal of Human Genetics · doi:10.1086/377159 · Cited by 98
A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
Abou‐Alfa, G. K., Capanu, M., O'Reilly, E. M., Ma, J., Chou, J. F., Gansukh, B., Shia, J., Kalin, M. F., Katz, S. S., Abad, L. W., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.008 · Cited by 98
Kramer, R. A., Marissen, W. E., Goudsmit, J., Visser, T., der Horst, M. C.-V., Bakker, A. Q., de Jong, M., Jongeneelen, M. A. C., Thijsse, S., Backus, H. H. J., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200526134 · Cited by 97
Cohn, A. L., Tabernero, J. M., Maurel, J., Nowara, E., Sastre, J., Chuah, B., Валериевич, К. М., Sakaeva, D., Mitchell, E. P., Dubey, S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt057 · Cited by 97
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
Zhang, J., Medeiros, L. J., & Young, K. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00351 · Cited by 97
In vitro and in silico assessment of the developability of a designed monoclonal antibody library
Wolf Pérez, A.-M., Sormanni, P., Andersen, J. S., Sakhnini, L. I., Rodriguez-Leon, I., Bjelke, J. R., Gajhede, A. J., De Maria, L., Otzen, D. E., Vendruscolo, M., et al. (2019) · mAbs · doi:10.1080/19420862.2018.1556082 · Cited by 97
Suffritti, C., Zanichelli, A., Maggioni, L., Bonanni, E., Cugno, M., & Cicardi, M. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12293 · Cited by 96
Kunik, V., & Ofran, Y. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt027 · Cited by 96
Atezolizumab for the treatment of breast cancer
Reddy, S. M., Carroll, E., & Nanda, R. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1732211 · Cited by 94
Lehrer‐Graiwer, J., Singh, P., Abdelbaky, A., Vucic, E., Korsgren, M., Baruch, A., Fredrickson, J. O., van Bruggen, N., Tang, M. T., Frendéus, B., et al. (2014) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2014.06.021 · Cited by 93
Gibson, T. J., McCarty, K. L., McFadyen, I. J., Cash, E., Dalmonte, P., Hinds, K. D., Dinerman, A. A., Alvarez, J. C., & Volkin, D. B. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22350 · Cited by 92
Development of a novel mammalian cell surface antibody display platform
Zhou, C., Jacobsen, F. W., Cai, L., Chen, Q., & Shen, D. L. (2010) · mAbs · doi:10.4161/mabs.2.5.12970 · Cited by 92
Pepinsky, R. B., Shao, Z., Ji, B., Wang, Q., Meng, G., Walus, L. R., Lee, X., Hu, Y., Graff, C. P., Garber, E. A., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183483 · Cited by 91
Interaction of antibodies with ErbB receptor extracellular regions
Schmitz, K. R., & Ferguson, K. M. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.008 · Cited by 91
Effect of bimagrumab on thigh muscle volume and composition in men with casting‐induced atrophy
Rooks, D. S., Laurent, D., Praestgaard, J., Rasmussen, S., Bartlett, M., & Tankó, L. B. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12205 · Cited by 90
Mazumdar, S. (2009) · mAbs · doi:10.4161/mabs.1.6.10195 · Cited by 90
New Opportunities and Challenges to Defeat Cancer Stem Cells
Ramos, E. K., Hoffmann, A. D., Gerson, S. L., & Liu, H. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.08.007 · Cited by 89
for the NEXUS Study Group, Taylor, P. C., Saurigny, D., Vencovský, J., Takeuchi, T., Nakamura, T., Matsievskaia, G., Hunt, B., Wagner, T., & Souberbielle, B. E. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1879-x · Cited by 89
Laboratory monitoring of hemophilia A treatments: new challenges
Lenting, P. J. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000849 · Cited by 89
Adalimumab in the Treatment of Immune-Mediated Diseases
Lapadula, G., Marchesoni, A., Armuzzi, A., Blandizzi, C., Caporali, R. F., Chimenti, S., Cimaz, R., Cimino, L., Gionchetti, P., Girolomoni, G., et al. (2014) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320140270s103 · Cited by 88
Remembering Emil von Behring: from Tetanus Treatment to Antibody Cooperation with Phagocytes
Kaufmann, S. H. E. (2017) · mBio · doi:10.1128/mbio.00117-17 · Cited by 88
Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
Garito, T., Roubenoff, R., Hompesch, M., Morrow, L., Gomez, K., Rooks, D., Meyers, C., Buchsbaum, M. S., Neelakantham, S., Swan, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13042 · Cited by 88
Hemmerle, T., Probst, P., Giovannoni, L., Green, A. J., Meyer, T., & Neri, D. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.421 · Cited by 87
Kuenen, B. C., Witteveen, P. O., Ruijter, R., Giaccone, G., Dontabhaktuni, A., Fox, F. E., Katz, T. L., Youssoufian, H., Zhu, J., Rowinsky, E. K., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2425 · Cited by 87
Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
Verdaguer, H., Tabernero, J. M., & Macarulla, T. M. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016635888 · Cited by 87
Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study
Poli, G. L., Bianchi, C., Virotta, G., Bettini, A., Moretti, R., Trachsel, E., Elia, G., Giovannoni, L., Neri, D., & Bruno, A. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0007 · Cited by 86
The diversity of H 3 loops determines the antigen‐binding tendencies of antibody CDR loops
Tsuchiya, Y., & Mizuguchi, K. (2016) · Protein Science · doi:10.1002/pro.2874 · Cited by 86
A Randomized, Placebo-Controlled Phase 2 Trial of CNTO 6785 in Chronic Obstructive Pulmonary Disease
Eich, A., Urbán, V. S., Jutel, M., Vlček, J., Shim, J. J., Трофимов, В. И., Liam, C. K., Kuo, P., Hou, Y., Xiao, J., et al. (2017) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2017.1335697 · Cited by 86
Product review on the Anti-PD-L1 antibody atezolizumab
Shah, N. J., Kelly, W., Liu, S. V., Choquette, K., & Spira, A. I. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1403694 · Cited by 85
Tsai, C. W., & Morris, S. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01320 · Cited by 83
Pujade-Lauraine, É., Fujiwara, K., Dychter, S. S., Devgan, G., & Monk, B. J. (2018) · Future Oncology · doi:10.2217/fon-2018-0070 · Cited by 83
Hu, Z. I., Bendell, J. C., Bullock, A., LoConte, N. K., Hatoum, H., Ritch, P., Hool, H., Leach, J. W., Sanchez, J., Sohal, D. P. S., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2425 · Cited by 82
Horn, L., Spigel, D. R., Gettinger, S. N., Antonia, S. J., Gordon, M. S., Herbst, R. S., Sequist, L. V. D., Chappey, C., Kowanetz, M., Sandler, A. B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8029 · Cited by 82
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
Smith, D. C., Chugh, R. K., Patnaik, A., Papadopoulos, K. P., Wang, M., Kapoun, A. M., Xu, L., Dupont, J., Stagg, R., & Tolcher, A. W. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0714-6 · Cited by 82
Genetically Engineered Antibody Molecules
Morrison, S. L., & Oi, V. T. (1989) · Advances in immunology · doi:10.1016/s0065-2776(08)60640-9 · Cited by 81
Saif, M. W., Knost, J. A., Chiorean, E. G., Kambhampati, S. R. P., Yu, D., Pytowski, B., Qin, A., Kauh, J. S. W., & O’Neil, B. H. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3134-3 · Cited by 81
Smith, D. C., Rosen, L. S., Chugh, R. K., Goldman, J. W., Xu, L., Kapoun, A. M., Brachmann, R. K., Dupont, J., Stagg, R., Tolcher, A. W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2540 · Cited by 81
Schwarz, M., Röttgen, P., Takada, Y., Gall, F. L., Knackmuss, S. H. J., Bassler, N., Büttner, C., Little, M., Bode, C., & Peter, K. (2004) · The FASEB Journal · doi:10.1096/fj.04-1513fje · Cited by 80
Hirsch, F. R., Dziadziuszko, R., Thatcher, N., Mann, H., Watkins, C. L., Parums, D. V., Speake, G., Holloway, B. R., Bunn, P. A., & Franklin, W. A. (2008) · Cancer · doi:10.1002/cncr.23282 · Cited by 80
Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
Erba, P. A., Sollini, M., Orciuolo, E., Traino, C., Petrini, M., Paganelli, G., Bombardieri, E., Grana, C. M., Giovannoni, L., Neri, D., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.101006 · Cited by 80
Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia
Seefried, L., Baumann, J., Hemsley, S., Hofmann, C., Kunstmann, E., Kiese, B., Huang, Y., Chivers, S., Valentin, M., Borah, B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci83731 · Cited by 80
Top companies and drugs by sales in 2019
Urquhart, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00047-7 · Cited by 80
Rakonjac, J., Jovanović, G., & Model, P. (1997) · Gene · doi:10.1016/s0378-1119(97)00298-9 · Cited by 79
Persaud, K., Tille, J., Liu, M., Zhu, Z., Jimenez, X., Pereira, D. S., Miao, H., Brennan, L. A., Witte, L., Pepper, M. S., et al. (2004) · Journal of Cell Science · doi:10.1242/jcs.01138 · Cited by 79
Bailey, K. M., Cost, C. R., Davis, I. J., Bender, J. G., Grohar, P. J., Houghton, P. J., Isakoff, M. S., Stewart, E. S., Laack, N. N., Yustein, J. T., et al. (2019) · F1000Research · doi:10.12688/f1000research.18139.1 · Cited by 79
Ramucirumab: First Global Approval
Poole, R. M., & Vaidya, A. (2014) · Drugs · doi:10.1007/s40265-014-0244-2 · Cited by 78
Probing a protein–protein interaction by in vitro evolution
Thom, G., Cockroft, A. C., Buchanan, A. G., Joberty-Candotti, C., Cohen, E. S., Lowne, D., Monk, P., Shorrock-Hart, C. P., Jermutus, L., & Minter, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602341103 · Cited by 78
Chiorean, E. G., Hurwitz, H. I., Cohen, R. B., Schwartz, J. D., Dalal, R., Fox, F. E., Gao, L., & Sweeney, C. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv144 · Cited by 78
Overman, M. J., LoRusso, P. M., Strickler, J. H., Patel, S. P., Clarke, S. J., Noonan, A. M., Prasanna, T., Amin, M. A., Nemunaitis, J. J., Desai, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4123 · Cited by 78
Eisenhardt, S. U., Schwarz, M., Bassler, N., & Peter, K. (2007) · Nature Protocols · doi:10.1038/nprot.2007.455 · Cited by 77
Sheehan, J., & Marasco, W. A. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0028-2014 · Cited by 75
Shimozato, O., Ugai, S., Chiyo, M., Takenobu, H., Nagakawa, H., Wada, A., Kawamura, K., Yamamoto, H., & Tagawa, M. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02257.x · Cited by 75
Vaccination Strategies and Immune Modulation of Atherosclerosis
Nilsson, J. Å., & Hansson, G. K. (2020) · Circulation Research · doi:10.1161/circresaha.120.315942 · Cited by 75
Current Clinical Trials in Pemphigus and Pemphigoid
Izumi, K., Bieber, K., & Ludwig, R. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00978 · Cited by 74
Spigel, D. R., Chaft, J. E., Gettinger, S. N., Chao, B. H., Dirix, L. Y., Schmid, P., Chow, L. Q. M., Chappey, C., Kowanetz, M., Sandler, A. B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.8028 · Cited by 73
Antibody modeling assessment II. Structures and models
Teplyakov, A., Luo, J., Obmolova, G., Malia, T. J., Sweet, R., Stanfield, R. L., Kodangattil, S., Almagro, J. C., & Gilliland, G. L. (2014) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24554 · Cited by 72
Besse, B., Johnson, M., Janne, P. A., Garassino, M. C., Eberhardt, W., Besse, B., Johnson, M., Janne, P. A., Garassino, M. C., Eberhardt, W., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31938-4 · Cited by 72
Gale, R. P., Mahmood, S., Devonport, H., Patel, P. J., Ross, A. H., Walters, G., Downey, L., Elsherbiny, S., Freeman, M., Berry, S., et al. (2019) · Eye · doi:10.1038/s41433-018-0300-3 · Cited by 72
Mammalian Cell Display for Antibody Engineering
Ho, M., & Pastan, I. H. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-554-1_18 · Cited by 69
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies
Aftimos, P. G., Rolfo, C. D., Rottey, S., Offner, F. C., Bron, D., Maerevoet, M., Soria, J., Moshir, M., Dreier, T., Rompaey, L. V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0613 · Cited by 69
Top drugs and companies by sales in 2018
Urquhart, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00049-0 · Cited by 69
Mease, P. J., Roussou, E., Burmester, G. R., Goupille, P., Gottlieb, A. B., Moriarty, S. R., Bénichou, O., Adams, D. H., Xu, W., & Nash, P. T. (2018) · Arthritis Care & Research · doi:10.1002/acr.23738 · Cited by 68
Affinity maturation of phage display antibody populations using ribosome display
Groves, M. A. T., Lane, S., Douthwaite, J. A., Lowne, D., Rees, D. G., Edwards, B. M., & Jackson, R. H. (2006) · Journal of Immunological Methods · doi:10.1016/j.jim.2006.04.002 · Cited by 67
Boosting antibody developability through rational sequence optimization
Seeliger, D., Schulz, P., Litzenburger, T., Spitz, J., Hoerer, S., Blech, M., Enenkel, B., Studts, J., Garidel, P., & Karow‐Zwick, A. R. (2015) · mAbs · doi:10.1080/19420862.2015.1017695 · Cited by 67
Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges
MacNabb, C., Patton, D., & Hayes, J. S. (2016) · Journal of Osteoporosis · doi:10.1155/2016/6217286 · Cited by 67
Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions
Smith, K. A., Pulsipher, A., Gabrielsen, D. A., & Alt, J. A. (2018) · American Journal of Rhinology and Allergy · doi:10.1177/1945892418787132 · Cited by 67
McWilliams, E. M., Lucas, C. R., Chen, T. F., Harrington, B. K., Wasmuth, R., Campbell, A. R., Rogers, K. A., Cheney, C. M., Mo, X. M., Andritsos, L. A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018025684 · Cited by 67
Parthiban, K., Perera, R. L., Sattar, M., Huang, Y., Mayle, S., Masters, E. W., Griffiths, D. T., Surade, S. B., Leah, R. A., Dyson, M. R., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1618673 · Cited by 67
Construction of a microphage variant of filamentous bacteriophage
Specthrie, L., Bullitt, E., Horiuchi, K., Model, P., Russel, M., & Makowski, L. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90858-h · Cited by 65
Vollmer, T. L., Wynn, D. R., Alam, M. S., & Valdes, J. M. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510384496 · Cited by 65
Lecerf, M., Kanyavuz, A., Lacroix‐Desmazes, S., & Dimitrov, J. D. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.06.012 · Cited by 64
Petrylak, D. P., Powles, T. B., Joaquim Bellmunt, B., Braiteh, F. S., Loriot, Y., Cruz, C., Burris, H. A., Kim, J. W., Teng, S.-L. M., Bruey, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.4501 · Cited by 63
Langley, R. G. B., Kimball, A. B., Nak, H., Xu, W., Pangallo, B. A., Osuntokun, O. O., Agada, N. O., & Reich, K. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15242 · Cited by 63
Affinity Maturation by Phage Display
Thie, H., Voedisch, B., Dübel, S., Hust, M., & Schirrmann, T. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-554-1_16 · Cited by 62
Jemec, G. B. E., Okun, M. M., Forman, S. B., Gulliver, W. P., Prens, E. P., Mrowietz, U., Armstrong, A. W., Geng, Z., Gu, Y., Williams, D., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17919 · Cited by 62
Ramucirumab: A Review in Hepatocellular Carcinoma
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01263-6 · Cited by 62
Bye, J. W., Platts, L., & Falconer, R. J. (2014) · Biotechnology Letters · doi:10.1007/s10529-013-1445-6 · Cited by 61
Quanz, M., Hagemann, U. B., Zitzmann-Kolbe, S., Stelte‐Ludwig, B., Golfier, S., Elbi, C., Mumberg, D., Ziegelbauer, K. B., & Schatz, C. A. (2018) · Oncotarget · doi:10.18632/oncotarget.26135 · Cited by 61
Biopanning of Phage Displayed Peptide Libraries for the Isolation of Cell-Specific Ligands
McGuire, M. J., Li, S., & Brown, K. C. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-569-9_18 · Cited by 59
Lavoisier, A., & Schlaeppi, J.-M. (2014) · mAbs · doi:10.4161/19420862.2014.985544 · Cited by 59
Immunotherapy for Mesothelioma: A Critical Review of Current Clinical Trials and Future Perspectives
Gray, S. G., & Mutti, L. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.11.23 · Cited by 58
Dervenis, N., Mikropoulou, A. M., Tranos, P., & Dervenis, P. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0548-1 · Cited by 58
A fully human IgG1 anti‐PD‐L1 MAb in an in vitro assay enhances antigen‐specific T‐cell responses
Grenga, I., Donahue, R. N., Lepone, L. M., Richards, J., & Schlom, J. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.27 · Cited by 57
A Review of Ranibizumab for the Treatment of Diabetic Retinopathy
Stewart, M. W. (2017) · Ophthalmology and Therapy · doi:10.1007/s40123-017-0083-9 · Cited by 57
Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
Teige, I., Mårtensson, L., & Frendéus, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00481 · Cited by 57
Kobayashi, N., Oyama, H., Katō, Y., Goto, J., Söderlind, E., & Borrebaeck, C. A. K. (2010) · Analytical Chemistry · doi:10.1021/ac902283n · Cited by 56
Sequist, L. V. D., Gray, J. E., Harb, W. A., López-Chávez, A., Doebele, R. C., Modiano, M., Jackman, D. M., Baggstrom, M. Q., Atmaca, A., Felip, E., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0695 · Cited by 56
Alfaleh, M. A., Jones, M. L., Howard, C. B., & Mahler, S. M. (2017) · Antibodies · doi:10.3390/antib6030010 · Cited by 55
Self-citationPlant/Bacterial Virus-Based Drug Discovery, Drug Delivery, and Therapeutics
Sokullu, E., Abyaneh, H. S., & Gauthier, M. A. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11050211 · Cited by 55
A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies
Jones, M. L., Seldon, T. A., Smede, M., Linville, A., Chin, D. Y., Barnard, R. T., Mahler, S. M., Munster, D. J., Hart, D. N. J., Gray, P. P., et al. (2010) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.02.001 · Cited by 54
Self-citationHuman anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6
Legouffe, É., Liautard, J., GAILLARD, J. P., Rossi, J.-F., Wijdenes, J., Bataille, R., Klein, B., & Brochier, J. (1994) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1994.tb06145.x · Cited by 54
Schmidt, M., Rüttinger, D., Sebastian, M., Hanusch, C. A., Marschner, N. W., Baeuerle, P. A., Wolf, A., Göppel, G., Oruzio, D. V., Schlimok, G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr625 · Cited by 54
A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma
Cohen, E. S., Dobson, C., Käck, H., Wang, B., Sims, D. A., Lloyd, C., England, E., Rees, D. G., Guo, H., Karagiannis, S. N., et al. (2014) · mAbs · doi:10.4161/mabs.28394 · Cited by 54
Four individually druggable MET hotspots mediate HGF-driven tumor progression
Basilico, C., Hultberg, A., Blanchetot, C., Jonge, N. D., Festjens, E., Hanssens, V., Osepa, S.-I., Boeck, G. D., Mira, A., Cazzanti, M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72316 · Cited by 54
Novel therapeutic options for cachexia and sarcopenia
Molfino, A., Amabile, M. I., Fanelli, F. R., & Muscaritoli, M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1208168 · Cited by 54
Avelumab: A Review in Metastatic Merkel Cell Carcinoma
Shirley, M. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0571-4 · Cited by 54
Factor XIa Inhibitors as New Anticoagulants
Quan, M. L. C., Pinto, D. J. P., Smallheer, J. M., Ewing, W. R., Rossi, K. A., Luettgen, J. M., Seiffert, D., & Wexler, R. R. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00173 · Cited by 54
Guselkumab for the treatment of psoriasis – evidence to date
Nogueira, M., & Torres, T. R. (2019) · Drugs in Context · doi:10.7573/dic.212594 · Cited by 54
ALTHEA Gold Libraries™: antibody libraries for therapeutic antibody discovery
Valadon, P., Pérez‐Tapia, S. M., Nelson, R. S., Guzmán-Bringas, O. U., Arrieta-Oliva, H. I., Gómez-Castellano, K., Pohl, M. A., & Almagro, J. C. (2019) · mAbs · doi:10.1080/19420862.2019.1571879 · Cited by 53
Nebbioso, M., Lambìase, A., Cerini, A., Limoli, P. G., Cava, M. L., & Greco, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071693 · Cited by 53
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
Malm, M., Frejd, F. Y., Ståhl, S., & Löfblom, J. (2016) · mAbs · doi:10.1080/19420862.2016.1212147 · Cited by 52
Studnicka, G. M., Soares, S., Better, M., Williams, R. E., Nadell, R., & Horwitz, A. H. (1994) · Protein Engineering Design and Selection · doi:10.1093/protein/7.6.805 · Cited by 51
Papp, K. A., Gooderham, M., Jenkins, R., Vender, R. B., Szepietowski, J. C., Wagner, T., Hunt, B., Souberbielle, B. E., & on behalf of the NEPTUNE investigators (2018) · British Journal of Dermatology · doi:10.1111/bjd.17195 · Cited by 51
Crotti, C., Agape, E., Becciolini, A., Biggioggero, M., & Favalli, E. G. (2019) · Drugs · doi:10.1007/s40265-019-01192-z · Cited by 51
Unexpected frameshifts from gene to expressed protein in a phage-displayed peptide library
Cárcamo, J. M., Ravera, M. W., Brissette, R. E., Dedova, O., Beasley, J. R., Alam-Moghé, A., Wan, C., Blume, A. J., & Mandecki, W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11146 · Cited by 50
Wichert, S., Juliusson, G., Johansson, Å. C. M., Sonesson, E., Teige, I., Wickenberg, A. T., Frendéus, B., Korsgren, M., & Hansson, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171205 · Cited by 50
Schliemann, C., Gutbrodt, K. L., Kerkhoff, A., Pohlen, M., Wiebe, S., Silling, G., Angenendt, L., Keßler, T., Mesters, R. M., Giovannoni, L., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0179 · Cited by 49
Discovery of diverse and functional antibodies from large human repertoire antibody libraries
Schwimmer, L. J., Huang, B. C. B., Giang, H. M., Cotter, R. L., Chemla-Vogel, D., Dy, F. V., Tam, E. M., Zhang, F., Toy, P., Bohmann, D. J., et al. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.02.010 · Cited by 49
Antibody Phage Display Libraries: Contributions to Oncology
Dantas-Barbosa, C., Brígido, M. M., & Maranhão, A. Q. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13055420 · Cited by 49
Cited by
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Animal immunization, in vitro display technologies, and machine learning for antibody discovery
Laustsen, A. H., Greiff, V., Karatt-Vellatt, A., Muyldermans, S., & Jenkins, T. P. (2021) · Trends in Biotechnology · doi:10.1016/j.tibtech.2021.03.003 · Cited by 147
Generation of peptides using phage display technology for cancer diagnosis and molecular imaging
Pung, H. S., Tye, G. J., Leow, C. H., Ng, W. K., & Lai, N. S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08380-x · Cited by 30
Generation and diversification of recombinant monoclonal antibodies
DeLuca, K. F., Mick, J. E., Ide, A. H., Lima, W. C., Sherman, L., Schaller, K. L., Anderson, S. M., Zhao, N., Stasevich, T. J., Varma, D., et al. (2021) · eLife · doi:10.7554/elife.72093 · Cited by 21
Arsiwala, A., Bhatt, R., van Niekerk, L., Quintero-Cadena, P., Ao, X., Rosenbaum, A., Bhatt, A., Smith, A., Yang, Y., Anderson, K., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2593055 · Cited by 16
Metadata
- Authors
- Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-08-28
- Volume
- 11
- Pages
- 1986-1986
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3044690826
- Cited by
- 273
- References
- 475
- FWCI
- 14.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.